The dismissal of antitrust counterclaims removes a major overhang for SSKN, but the survival of defamation and false marking claims means discovery will proceed on Strata's public statements about the litigation. Monitor for settlement discussions or adverse discovery outcomes that could lead to damages. The court's prior criticism of Strata's characterization of the stipulation as an 'injunction' increases risk of an adverse jury finding on those surviving claims.
Price Chart
Executive Summary
The court partially granted and partially denied Strata's motion to dismiss LaserOptek's counterclaims. The antitrust counterclaims (monopolization/attempted monopolization) were dismissed with prejudice under Noerr-Pennington immunity. However, key defamation and commercial disparagement claims survive, specifically regarding Strata's characterization of a joint stipulation as a court-ordered injunction and its CEO's statement that the judge found LaserOptek's information 'fraudulent.' This ruling keeps litigation risk alive for Strata, as the surviving claims could lead to discovery and potential damages, while the dismissal of antitrust claims removes a significant existential threat to Strata's business model of enforcing its patent and false advertising positions through litigation.
Court Ruling Details
Key Facts
- Court dismissed LaserOptek's antitrust counterclaims (Counts I & II) with prejudice, finding Strata protected by Noerr-Pennington immunity.
- Court denied dismissal of defamation claims regarding Strata's statements that it was 'awarded an injunction' and that the judge found LaserOptek's information 'fraudulent.'
- Court dismissed defamation claims regarding statements that Pallas lasers 'cannot be billed,' 'do not technically work even close to' Strata lasers, and that LOA violated AMA policy.
- Court denied dismissal of false marking counterclaim (Count V) regarding Strata's claim of holding 'three key granted patents' which were actually patent applications.
- Commercial disparagement claim survives only for the October 2025 press release and the August 2025 earnings call statement about the judge's 'fraudulent information' finding.
Financial Impact
Litigation risk remains material but unquantified; LOA alleges over $1 million in annual capital and recurring revenue lost due to Strata's statements. Antitrust exposure (potentially treble damages) removed entirely.
Risk Factors
- Surviving defamation and false marking claims expose Strata to discovery costs and potential damages.
- CEO Dolev Rafaeli is individually named in surviving claims, creating personal liability risk.
- Court's prior criticism of Strata's statements could prejudice a jury against Strata on the surviving claims.
- False marking claim (Count V) could result in statutory penalties if Strata knowingly misrepresented patent applications as issued patents.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 court opinions.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-9a4f8d9745-SSKN |
| COURT-RULING Data (Synthetic) | court-c778fa6dd0-SSKN |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 9w ago | Court Ruling | $0.000200 | awaiting T+60 | — | $0.000200 (−0.00%) |
Mar 2, 2026 34w ago | 15-12G | $0.2600 $0.1400 | ▲ +46.15% | ▲ +56.47% | $0.000200 (+99.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers